OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Autophagy-Related Chemoprotection against Sorafenib in Human Hepatocarcinoma: Role of FOXO3 Upregulation and Modulation by Regorafenib
Flavia Fondevila, Carolina Méndez‐Blanco, Paula Fernández‐Palanca, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11770-11770
Open Access | Times Cited: 11

Showing 11 citing articles:

FOXO3a in cancer drug resistance
Ying Liu, Yu Wang, Xiaoge Li, et al.
Cancer Letters (2022) Vol. 540, pp. 215724-215724
Closed Access | Times Cited: 54

The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma
Kyoko Oura, Asahiro Morishita, Sae Hamaya, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2805-2805
Open Access | Times Cited: 25

Pathogenesis of Hepatocellular Carcinoma: The Interplay of Apoptosis and Autophagy
Elias Kouroumalis, Ioannis Tsomidis, Argyro Voumvouraki
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1166-1166
Open Access | Times Cited: 21

Unraveling the interplay between RAS/RAF/MEK/ERK signaling pathway and autophagy in cancer: From molecular mechanisms to targeted therapy
Yunli Huang, Yongqi Zhen, Yanmei Chen, et al.
Biochemical Pharmacology (2023) Vol. 217, pp. 115842-115842
Open Access | Times Cited: 18

Pharmacogenomic insights: IL-23R and ATG-10 polymorphisms in Sorafenib response for hepatocellular carcinoma
Asmaa Elsheshtawy, Rehab H. Werida, Monir Bahgat, et al.
Clinical and Experimental Medicine (2025) Vol. 25, Iss. 1
Open Access

Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT‐FOXO3 signalling pathway
Yizhe Cheng, Ping Zhan, Jing Lü, et al.
Liver International (2023) Vol. 43, Iss. 7, pp. 1577-1592
Closed Access | Times Cited: 11

Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation
Paula Fernández‐Palanca, Tania Payo‐Serafín, Beatriz San‐Miguel, et al.
Acta Pharmacologica Sinica (2022) Vol. 44, Iss. 5, pp. 1066-1082
Open Access | Times Cited: 18

Effects of fasting on FOXO3 expression as an anti-aging biomarker in the liver
Novi Silvia Hardiany, Muhammad Alifian Remifta Putra, Raya Makarim Penantian, et al.
Heliyon (2023) Vol. 9, Iss. 2, pp. e13144-e13144
Open Access | Times Cited: 5

AURKA Activates FOXO3a to Form a Positive Feedback Loop in the Proliferation and Migration of Keloid Fibroblasts
Xi Chu, Jiaqi Sun, Siya Dai, et al.
Advances in Wound Care (2024)
Closed Access

Bibliometric study on the utilization of sorafenib in hepatocellular carcinoma
Wenjun Meng, Yihang Luo, Zhao Lu, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access

Page 1

Scroll to top